Laevolac (Lactulose)

Lactulose is a synthetic disaccharide that reaches the colon unchanged. Colonic bacteria hydrolyze it to short‑chain fatty acids, which increase the osmotic pressure in the lumen, pulling water into the bowel and softening stool. The acidic environment also converts ammonia (NH3) to ammonium (NH4+), reducing its absorption into the bloodstream and helping to lower systemic ammonia levels.

The appropriate dose of Laevolac is determined by the prescribing clinician based on the indication, patient age, weight, and response to therapy. For constipation, the dose is typically started low and titrated upward until regular bowel movements are achieved. For hepatic encephalopathy, dosing aims to produce two to three soft stools per day. Exact dosing instructions should be obtained from a qualified healthcare provider.

Lactulose is classified as a Category B medication in many jurisdictions, indicating no proven risk in animal studies but limited human data. It is generally considered safe for use during pregnancy and lactation when clearly needed, as it is poorly absorbed and acts locally in the gut. Nevertheless, pregnant or nursing patients should discuss potential benefits and risks with their obstetrician or physician before starting therapy.

To place an order, visit the product page for Laevolac on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Compared with stimulant laxatives such as bisacodyl, lactulose works by an osmotic mechanism rather than stimulating intestinal muscle contractions, resulting in a gentler onset of action and fewer cramping side effects. Unlike bulk‑forming agents, lactulose does not require high fiber intake. In hepatic encephalopathy, lactulose is the preferred agent because of its ability to lower ammonia, a benefit not shared by most other laxatives.

Laevolac should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Ensure the bottle is tightly closed after each use. Do not freeze the product, and keep it out of reach of children. If the solution appears discolored or contains particles, discard it and obtain a new supply.

Laevolac is taken orally, usually as a liquid solution. The dose is measured with a calibrated spoon or cup provided by the manufacturer. It can be taken with or without food, and patients are advised to follow the prescriber’s instructions regarding timing and volume. Adequate fluid intake should be maintained throughout treatment to support its osmotic action.

The most serious adverse events include severe dehydration, electrolyte disturbances such as hypokalemia, and rare cases of colonic pseudo‑obstruction (Ogilvie’s syndrome). Allergic reactions presenting as rash, itching, or swelling may also occur. Patients should seek immediate medical attention if they experience dizziness, fainting, rapid heartbeat, or signs of an allergic response while using Laevolac.

Laevolac is contraindicated in individuals with known hypersensitivity to lactulose or any component of the formulation. It should be used with caution, or avoided, in patients with intestinal obstruction, perforation, or severe inflammatory bowel disease. Patients with uncontrolled diabetes or significant renal impairment should be evaluated carefully before initiating therapy, and the decision should be guided by a qualified healthcare professional.